In short
Epcoritamab is an investigational bispecific antibody being studied in clinical trials for the treatment of various B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and other aggressive mature B-cell neoplasms. This article summarizes key information from ongoing clinical trials evaluating the safety and efficacy of epcoritamab in patients with relapsed or refractory disease.
At a glance
- Drug Name
- Epcoritamab (also known as ABBV-GMAB-3013, GEN3013, DuoBody-CD3xCD20)
- Drug Type
- Bispecific antibody targeting CD3 and CD20
- Administration
- Subcutaneous injection
- Conditions Studied
- Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Burkitt Lymphoma, Waldenström Macroglobulinemia, other aggressive B-cell neoplasms
- Trial Phases
- Phase 1b, Phase 2
- Key Outcomes Measured
- Safety, tolerability, overall response rate, complete response rate, progression-free survival, overall survival
- Common Side Effects Monitored
- Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), other neurological toxicities
- Treatment Schedule
- Typically 28-day cycles, with varying dosing schedules depending on the trial
What is Epcoritamab?
Epcoritamab is an investigational drug being developed to treat various types of B-cell lymphomas, which are cancers that affect a type of white blood cell called B-cells. It is a new type of treatment known as a bispecific antibody, which is a synthetic protein designed to activate the immune system to target cancer cells.
Epcoritamab is also known by other names, including:
- GEN3013
- ABBV-GMAB-3013
- DuoBody-CD3xCD20
How Does Epcoritamab Work?
Epcoritamab works in a unique way by connecting two important parts of the immune system:
- It binds to a protein called CD20, which is found on B-cells (including cancerous B-cells).
- It also binds to CD3, a protein found on T-cells, which are another type of immune cell that helps fight cancer.
By connecting these two cell types, epcoritamab helps activate T-cells to recognize and destroy cancerous B-cells. This targeted approach aims to be more effective and potentially have fewer side effects than traditional chemotherapy.
What Conditions Does Epcoritamab Treat?
Epcoritamab is being studied to treat several types of B-cell lymphomas, including:
- Diffuse Large B-Cell Lymphoma (DLBCL): An aggressive type of non-Hodgkin lymphoma
- Follicular Lymphoma (FL): A slow-growing type of non-Hodgkin lymphoma
- Waldenstrom Macroglobulinemia (WM): A rare type of slow-growing non-Hodgkin lymphoma
- Chronic Lymphocytic Leukemia (CLL) and Richter Syndrome: Types of blood and bone marrow cancers
These conditions are typically treated when they have relapsed (come back after treatment) or become refractory (stopped responding to previous treatments).
How is Epcoritamab Administered?
Epcoritamab is given as a subcutaneous injection, which means it is injected under the skin. The treatment is usually given in cycles, with each cycle lasting 28 days. The dosing schedule may vary depending on the specific condition being treated and the stage of treatment.
Typically, patients start with lower doses that gradually increase to the full dose over the first few weeks of treatment. This approach, known as "step-up dosing," is used to help reduce the risk of side effects.
Current Clinical Trials
Epcoritamab is currently being studied in several clinical trials for different conditions and treatment approaches. Some notable trials include:
- A study combining epcoritamab with other treatments before and after stem cell transplantation for large B-cell lymphomas
- A trial investigating epcoritamab in pediatric patients with relapsed or refractory B-cell lymphomas
- A study looking at epcoritamab treatment for patients with follicular lymphoma who didn't achieve a complete response with initial therapy
Potential Side Effects
As with any cancer treatment, epcoritamab can cause side effects. Some of the most important side effects to be aware of include:
- Cytokine Release Syndrome (CRS): This is an inflammatory response that can cause fever, chills, and other flu-like symptoms. It's usually mild but can sometimes be severe.
- Neurological effects: Some patients may experience confusion, difficulty speaking, or other neurological symptoms.
- Infections: Because epcoritamab affects the immune system, it may increase the risk of infections.
Doctors closely monitor patients for these and other side effects during treatment. Some trials are even exploring ways to prevent or reduce these side effects, such as using other medications before epcoritamab treatment.
Future Prospects
While epcoritamab is still an investigational drug, early results from clinical trials have been promising. Researchers are exploring its use in various types of lymphomas and at different stages of treatment. If successful, epcoritamab could provide a new option for patients who have not responded well to other treatments.
As research continues, we may learn more about how effective epcoritamab is, which patients benefit most from it, and how to best manage any side effects. Patients interested in epcoritamab should discuss with their doctors whether participating in a clinical trial might be appropriate for their situation.